ArticleIJID regions2026
Need for gender-neutral human papillomavirus vaccination: Lessons from a retrospective epidemiologic investigation of human papillomavirus infections among outpatients presenting to a tertiary dermatology hospital in Central China from 2017 to 2024.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to analyze human papillomavirus (HPV) prevalence, genotype distribution, and associated clinical characteristics among outpatient individuals attending a tertiary dermatology hospital in Central China, to inform public health strategies. Methods: A retrospective analysis was conducted on electronic health records of 3001 outpatients from 2017 to 2024. HPV genotyping was performed using a flow fluorescent hybridization assay detecting 27 genotypes (17 high-risk [HR] and 10 low-risk [LR] types). Results: The overall HPV positivity rate was 31.4%, significantly higher in males than females (34.8% vs 28.9%, Conclusion: The findings highlight high HPV prevalence and significant co-infection rates in Central China, emphasizing the risk of hidden HR-HPV transmission. Implementing gender-neutral vaccination (covering prevalent genotypes including 6, 11, 16, 18, 52, and 58) and enhancing screening (e.g. colposcopy, self-sampling in rural areas) are crucial public health priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.